Hydrochloric Acid → N-((5,5-difluoropiperidin-3-yl)methyl)-7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-amine

HRID 57615

Reaktionsgleichung

Reaktionsgleichung von HRID 57615
[F:1][C:2]1([F:39])[CH2:7][CH:6]([CH2:8][NH:9][C:10]2[C:19]3[C:14](=[N:15][CH:16]=[CH:17][N:18]=3)[CH:13]=[C:12]([C:20]3[CH:25]=[CH:24][C:23]([N:26]4[CH2:31][CH2:30][O:29][CH2:28][CH2:27]4)=[CH:22][CH:21]=3)[N:11]=2)[CH2:5][N:4](C(OC(C)(C)C)=O)[CH2:3]1.Cl>>[F:39][C:2]1([F:1])[CH2:3][NH:4][CH2:5][CH:6]([CH2:8][NH:9][C:10]2[C:19]3[C:14](=[N:15][CH:16]=[CH:17][N:18]=3)[CH:13]=[C:12]([C:20]3[CH:21]=[CH:22][C:23]([N:26]4[CH2:27][CH2:28][O:29][CH2:30][CH2:31]4)=[CH:24][CH:25]=3)[N:11]=2)[CH2:7]1

Komponenten

3

Edukt 2

HCID 313Hydrochloric AcidHCID 71113804Tert-butyl 3,3-difluoro-5-((7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-ylamino)methyl)piperidine-1-carboxylate

Produkt 1

HCID 71113816N-((5,5-difluoropiperidin-3-yl)methyl)-7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-amine

Versuchsvorschrift

tert-Butyl 3,3-difluoro-5-((7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-ylamino)methyl)piperidine-1-carboxylate from step A (227 mg, 0.42 mmol) was treated with HCl solution (in EtOAc, 5 N) at room temperature until the reaction was finished. The volatiles were removed under reduced pressure, dissolved in dichloromethane (5 mL), and neutralized with ammonium hydroxide. The dichloromethane phase was concentrated to afford N-((5,5-difluoropiperidin-3-yl)methyl)-7-(4-morpholinophenyl)pyrido[4,3-b]pyrazin-5-amine. MS (m/z): 441 (M+H)+.

Aufarbeitung

  1. customThe volatiles were removed under reduced pressure
  2. dissolutiondissolved in dichloromethane (5 mL)
  3. concentrationThe dichloromethane phase was concentrated

Quellen und Nachweise

ORD-Eintrag
ord-75b30ea9a5ba40a6bc265c2846b58848
Quelldatensatz
uspto-grants-2016_09
Patentnummer
US09434726B2

Verknüpfte Notizen

Wird geladen…